Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Kaposi Sarcoma Market Anticipated to Grow at a CAGR of 4.12% During Forecast Period 2020-2025


Kaposi Sarcoma Marke

iCrowdNewswire   Oct 21, 2020  10:00 AM ET

Kaposi Sarcoma Market size is valued at $122.4m by 2019, and is anticipated to grow at a CAGR of 4.12% during the forecast period 2020-2025. The Kaposi Sarcoma Market growth rate is attributed to the rising incidence of cancer. Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels, abnormal cells of KS form purple, red, or brown blotches or tumors on the skin called as lesions. As, Kaposi sarcoma is easily caught by a body with weaker immune system, the chances of Kaposi sarcoma occurrence increase, which in turn fuel the market’s growth. From improvement’s made on reduction in drug resistance, lowering failure rate, few side effects, and the decreasing case-fatality ratios to the growing emphasis on combination therapy is anticipated to propel the Kaposi Sarcoma Market during the forecast period 2020-2025.

Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=17349

Report Price: $ 4500 (Single User License)  

By Treatment – Segment Analysis

Antiretroviral Therapy (HAART) segment held the largest share in the market owing to rising incidence rate of AIDS-associated Kaposi sarcoma over other types.  Also there has been a rising preference for this treatment and the high cost of treatment is anticipated to bolster the market growth. Furthermore, for people with epidemic Kaposi sarcoma, antiretroviral treatment (ART) for HIV/AIDS is usually used before any other treatments to treat the tumor and reduce symptoms and rarely, ART can make preexisting infections and the Kaposi sarcoma worse. The segment is poised to grow at a CAGR of  of 3.44%

By Geography – Segment Analysis

North America dominated the Kaposi Sarcoma Market with a share of 38% in 2019. The application of Kaposi Sarcoma has grown rapidly over the last few years owing to the presence of a large number of leading players and the increasing costs of drugs. In addition, the easy availability of advanced drugs and the technologically advanced healthcare continues to expand its market. With the increasing prevalence of Kaposi sarcoma and HIV in May 2019, The USFDA granted breakthrough therapy designation to Celgene’s pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma. Moreover, there are high number of R&D initiatives undergoing the treatment and the diagnosis of the Kaposi sarcoma to cater the Kaposi Sarcoma Market in the forecast period of 2020-2025.

Talk to one of our sales representative about the full report by providing your details in the link below:

https://www.industryarc.com/support.php?id=17349

Drivers – Kaposi Sarcoma Market

With the rise in demand of patients undergoing organ transplant procedures, there has been a growth in the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the American Cancer Society (ACS), February 2016 data findings, around 1 in 200 transplant patients in the U.S. suffer from Kaposi sarcoma which can be considered as a Kaposi Sarcoma key driver of the market during the forecast period 2020-2025.

Challenges – Kaposi Sarcoma Market

The major challenge for the market is the overall high cost of cancer treatment; there has been lack of awareness about this cancer, irregular availability of chemotherapy and HAART, lack of radiotherapy services. For instance, the prices of major drugs used for the treatment of Kaposi sarcoma, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel in combination with HAART, are increasing significantly, making them unaffordable for middle- and lower-income group patients.

Acquisitions/Product Launches

Key Takeaways

Kaposi Sarcoma Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Kaposi Sarcoma Market. In 2019, Kaposi Sarcoma Market share is fragmented by the top ten players present in the market. Kaposi Sarcoma Market top 10 companies are Eli Lilly and Company, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, GlaxoSmithKline, Merck, Quest Diagnostics, Navidea Biopharmaceuticals Inc., MBio Diagnostics, Cleveland Clinic and others.

Related Reports:

Aerial Imaging Market

https://www.industryarc.com/Report/16300/aerial-imaging-market.html

Automotive Artificial Intelligence Market

https://www.industryarc.com/Report/18530/automotive-artificial-intelligence-market-research-report.html

About IndustryARC : IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.



Contact Information:

Venkat Reddy
Sales Director
Email: venkat@industryarc.com
Website: https://www.industryarc.com
Phone: (+1) 970-236-3677






Keywords:    Kaposi Sarcoma market, Kaposi Sarcoma market size, Kaposi Sarcoma industry, Kaposi Sarcoma market share, Kaposi Sarcoma top 10 companies, Kaposi Sarcoma market report, Kaposi Sarcoma industry outlook

Tags:    Reportedtimes, Wire, Extended Distribution, iCN Internal Distribution, Research Newswire, English